Bio-Rad Laboratories Inc (BIO)
Bio-Rad Laboratories, Inc. is a common stock listing on the New York Stock Exchange. The company develops, manufactures, and distributes life science research and clinical diagnostic products across the United States and international markets, including Europe, Asia, Canada, and Latin America. Its operations are organized into two segments: Life Science and Clinical Diagnostics. The Life Science segment provides instruments, systems, reagents, and consumables used to separate, purify, characterize, and measure biological materials such as cells, proteins, and nucleic acids in research, biopharmaceutical, manufacturing, quality control, food safety, and education settings. The Clinical Diagnostics segment supplies diagnostic test systems, informatics tools, test kits, quality controls, and related software for hospital, reference, transfusion, and physician office laboratories. Founded in 1952, Bio-Rad Laboratories is headquartered in Hercules, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-BIO
|
$347.76
|
16.5% Upside
|
Fair
|
$297
|
-0.5% Downside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
47.0x
|
1.2x
|
3.1x
|
8.117 B
|
2.442 B
|
14.5%
|
78.1%
|
3.5
|
—
|
211.6%
|
